CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA



Sixteenth meeting of the Plants Committee Lima (Peru), 3-8 July 2006

Annotations for species in Appendices II and III

MEDICINAL PLANTS

Membership (as decided by the Committee)

- Chairman: Uwe Schippmann (Germany)
- Members: Observers from Canada, China, the United States of America and the American Herbal Products Association.

Mandate

Under document PC16 Doc.17.1

Discuss and decide upon issues raised in paragraph 18.

Clarify the definition of "pharmaceutical products" in proposed new annotation # 10.

According to Decision 13.52:

The Plants Committee shall draft proposals to amend the Appendices in this respect for the Depositary Government to present for consideration at the 14th meeting of the Conference of the Parties.

Recommendations

The WG recommends to the Plants Committee:

- 1. to endorse the proposed changes to the annotations outlined in tables 1 and 2 of document PC16 Doc. 17.1 as laid out in paragraphs 7 to 15; except,
 - a) to remove the term "pharmaceutical" from the proposed revision of #10 in table 2 of document PC16 Doc. 17.1; and in addition
 - b) to annotate *Hydrastis canadensis* with "Designates underground parts (i.e. roots, rhizomes): whole, parts and powdered"; and
 - c) to annotate *Podophyllum hexandrum* with #10 as described in recommendation a), above.

- 2. that, according to Decision 13.52, the Scientific Authority of Germany draft a single amendment proposal with respect to recommendations 1 to 4.
- 3. that a glossary of terms similar to table 3 of PC 16 Doc. 17.1 be included in the Interpretation to the Appendices after CoP14, a draft of which will be submitted in the amendment proposal.